# Semax — source links

WPF · Peptides in 2 · Brain, Pain & Neuropeptides · Episode 01

Source numbers match the revised film. Original scientific sources checked October 16; added history sources checked October 17, 2026.

1. FDA GSRS — Semax, UNII I5FAL2585H. https://precision.fda.gov/ginas/app/ui/substances/I5FAL2585H
2. Filippenkov et al., Genes (2020) — Rat cerebral ischemia–reperfusion transcriptome study. PMID 32580520; PMCID PMC7350263. https://pmc.ncbi.nlm.nih.gov/articles/PMC7350263/
3. Gusev et al. (1997) — Semax in acute hemispheric ischemic stroke. PMID 11517472. English abstract accessed; full Russian article not verified. https://pubmed.ncbi.nlm.nih.gov/11517472/
4. FDA (2026) — Staff briefing for the July 23–24 Pharmacy Compounding Advisory Committee. https://www.fda.gov/media/193348/download
5. FDA — Compounded drug risks and the approval distinction. https://www.fda.gov/drugs/human-drug-compounding/understanding-risks-compounded-drugs

See the production brief for the claim-to-source map and access limitations. This film contains no dosing instructions.

6. Semax manufacturer — development chronology: 1980 project start and 1985 synthesis; attributed historical account. https://semax.ru/chto_eto/istorija/
7. Russian Ministry of Health and Medical Industry — order No. 294, December 20, 1994, including Semax and its 0.1% preparation. Primary order reproduced by Jurbase. https://jurbase.ru/texts/sector159/tez59529.htm
8. Moscow State University — institutional biography of Igor Petrovich Ashmarin. https://vov.bio.msu.ru/project/ashmarin-igor-petrovich/
9. Russian Academy of Sciences — institutional biography of Nikolai Fyodorovich Myasoedov. https://www.ras.ru/news/shownews.aspx?id=aeb64c12-bc73-46eb-8c5d-fe39ea49912e
10. Ashmarin and colleagues (1997) — developers' account of fifteen years of design and study; English abstract accessed. PMID 9173745. https://pubmed.ncbi.nlm.nih.gov/9173745/

Dates of project start, synthesis, publication and medical registration describe different milestones. The film attributes the development dates to the manufacturer's timeline. Registration provides a dated medical-history milestone; it does not document uninterrupted use by a defined patient group. The clinical comparison's English abstract does not specify allocation or blinding. The FDA source is a dated staff briefing, not a final committee decision or a current legal ruling.